MMI0 Stock Overview
A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MEI Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$11.40 |
| 52 Week Low | US$3.58 |
| Beta | 0.92 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -63.79% |
| 33 Year Change | -93.14% |
| 5 Year Change | -93.84% |
| Change since IPO | -96.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| MMI0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -63.8% | -17.2% | 8.2% |
Return vs Industry: MMI0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: MMI0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| MMI0 volatility | |
|---|---|
| MMI0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MMI0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MMI0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 102 | David Urso | meipharma.com |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. Fundamentals Summary
| MMI0 fundamental statistics | |
|---|---|
| Market cap | €44.15m |
| Earnings (TTM) | -€33.73m |
| Revenue (TTM) | €52.34m |
0.8x
P/S Ratio-1.3x
P/E RatioIs MMI0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MMI0 income statement (TTM) | |
|---|---|
| Revenue | US$58.77m |
| Cost of Revenue | US$0 |
| Gross Profit | US$58.77m |
| Other Expenses | US$96.65m |
| Earnings | -US$37.87m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -64.44% |
| Debt/Equity Ratio | 0% |
How did MMI0 perform over the long term?
See historical performance and comparison